Mm

... get these clinical trials across the finish line.

And so there's some benefits of being in an academic setting as well as in a public company.

And the academic part helps in that, you know, for one, I have a personal connection with patients, and so I see them battle their cancers, and I see when their tumors come back because the cancer has developed a resistance to the drugs they're on.

And so not only is this a scientific question, but it's a pretty humanistic one in that, you know, I believe the main part of my job is to give patients hope.

And when these cancers return, you know, you really see the hope leave these patients' eyes.

And so we try to provide them hope based on good science and having identified mechanisms of resistance and developing drugs for resistance, and we're really here to give hope, not only with surgeries, but with new drugs.

Like, I guess what I'll start here with the base is like, what is the cause for resistance to cancer drugs, and how can that be addressed?

Mm

... get these clinical trials across the finish line.

And so there's some benefits of being in an academic setting as well as in a public company.

And the academic part helps in that, you know, for one, I have a personal connection with patients, and so I see them battle their cancers, and I see when their tumors come back because the cancer has developed a resistance to the drugs they're on.

And so not only is this a scientific question, but it's a pretty humanistic one in that, you know, I believe the main part of my job is to give patients hope.

And when these cancers return, you know, you really see the hope leave these patients' eyes.

And so we try to provide them hope based on good science.

Like, I guess what I'll start here with the base is like, what is the cause for resistance to cancer drugs, and how can that be addressed?

How far away are other people designing agents and hacking agents and cybersecurity agents from being able to replicate what you guys are doing? Is there some sort of secret sauce working with BitTensor and working with these incentivized miners that gives you guys an edge over all of the various companies that are focused on AI-powered cybersecurity?

Yeah, definitely.

It's a combination of having an open competition where everyone can contribute, not just people from San Francisco or sitting in offices in New York City.

And that it's kind of like the people who were maybe like living in, in their mom's basement with a chip on their shoulder.

Like I'm going to prove that I'm the best.

And yeah, I mean, cybersecurity is kind of like that.

Like there, there are brilliant people from everywhere in the world looking to do something good, not necessarily like hack something.

So this is a for-profit company built on top of the power of this BitTensor subnet?

I, I'd love just to hear the, the early story here because obviously a very important intersection that you've, you've been working at over the years and love to hear a little bit more about it.

Yeah, thanks.

Uh, thanks for that introduction.

And, uh, yeah, um, my journey has been, uh, you know, through science and, and, uh, and I've had the fortune of living through very interesting times where the, uh, the science has just, uh, uh, exploded in terms of our ability to impact, uh, the human body and disease.

And I first became, uh, fascinated by science as an undergrad at Stanford when, uh, when, uh, gene, uh, manipulation was first discovered and, uh, used at Genentech, and I had the opportunity to work as a summer intern at Genentech and just saw the, the, the immense potential of being able to impact, uh, genetic diseases, uh, uh, through, uh, through medicines, uh, that, uh, are from, uh, genes.

Uh, and then I had the fortune of working at the Pasteur Institute and working on immunology and cancer research.

And so I always wanted to encompass, uh, and bring, uh, science into, uh, whatever I did.

And just lay the landscape of, of what drug resistance in oncology means to the world in 2026, 'cause it's a big problem.